7 Feb 2013

17 Jan 2013

Genentech has released a reserve stock of Tamiflu® (oseltamivir phosphate) 75 mg capsules that carry different packaging from what is currently available on the market in the U.S.

4 Apr 2012

14 Feb 2012

28 Apr 2011

6 Oct 2010

Genentech, a member of the Roche Group, announced today that ample supplies of Tamiflu (oseltamivir phosphate), a prescription antiviral medicine to treat flu, will be widely available at U.S. pharmacies this flu season.

2 Jun 2010

Genentech, Inc. announced today that it has accepted the recommendation of an independent Data and Safety Monitoring Board (DSMB) to stop enrollment into the MAIN trial, a Phase III clinical study evaluating the efficacy and safety of Avastin® (bevacizumab) when added to Rituxan® (rituximab) plus CHOP (cyclophosphamide/doxorubicin/vincristine/prednisone) chemotherapy in patients with Diffuse Large B-Cell Lymphoma (DLBCL).

27 May 2010

Genentech, Inc. announced today that the U.S. Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) will discuss the company's two supplemental Biologics License Applications (sBLAs) for Avastin® (bevacizumab) for the treatment of women who have not received chemotherapy for advanced (metastatic) HER2-negative breast cancer during an advisory committee meeting on July 20, 2010.

11 Dec 2009

Genentech, Inc. announces study of Avastin® (bevacizumab) in early-stage breast cancer (E5103) will resume enrollment and continue as planned.

9 Mar 2009

Genentech, Inc. announced today that the U.S. Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) will discuss the company's supplemental Biologics License Application (sBLA) for Avastin® (bevacizumab) for people with previously treated glioblastoma during an advisory committee meeting on March 31, 2009.

22 May 2001